CT:AVCN Avicanna Inc

Avicanna Inc., a biopharmaceutical company, focuses on the research, development, cultivation, manufacture, and commercialization of plant-derived cannabinoid-based products and extracts for the use in medical, consumer health, and pharmaceutical industries internationally. The company provides pharmaceutical grade cannabinoids, including tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), and other rare cannabinoids; active pharmaceutical ingredients (APIs); feminized seeds; and bulk formulations under the Aureus Santa Marta brand. It also offers CBD based derma-cosmetic consumer products, such as beauty treatment, moisture and protection, and specialized care products under the Pura Earth brand; and medical cannabis/phyto-therapeutic products for the medical or homeopathic use under the Rho Phyto brand. In addition, the company provides pharmaceutical products focusing on skin disorders, including epidermolysis bullosa, eczema, and general skin problems comprising acne, erythema, and dryness; and neurological disorders, such as neuropathic pain, epilepsy, Parkinson's disease and multiple sclerosis, and nociceptive pain resulting from inflammatory and joint disorders, as well as a topical cream for rare genetic skin disorders. Avicanna Inc.was founded in 2016 and is headquartered in Toronto, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol AVCNF.

This company has cross-listed shares that trade in the U.S. as the symbol AVCNF.

0.38 CAD
As of 03/24/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Unknown
Industry:  Drug Manufacturers-Specialty &
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    Toronto Stock Exchange
Exchange country:   Canada
Market cap:   20,168,330 CAD
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy